# US 2026/0083740 A1 · Use of tavapadon in treating parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083740 A1
- Document ID: US20260083740A1
- Status: Published application
- Kind: A1
- Application number: 19/337,808
- Filed: 2025-09-23
- Published: 2026-03-26
- Earliest claimed: 2024-09-25
- Applicants: Cerevel Therapeutics, LLC
- Inventors: Sridhar Duvvuri
- Web page: https://patentgrep.com/patent/US20260083740A1

## CPC

- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/16: Anti-Parkinson drugs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods for treating a patient diagnosed with Parkinson's Disease (PD) by administering an escalating dose of tavapadon and monitoring efficacy of PD treatment.

## Claims

### Claim 1

A method for treating Parkinson's Disease in a patient, wherein the method comprises:
a titration phase comprising orally administering to the patient a daily dose of tavapadon in eight sequential dose escalation steps 1-8, wherein
step 2 comprises administering to the patient a dose of 0.5 mg per day of tavapadon on days 5-8 of treatment,
step 6 comprises administering to the patient a dose of 2.25 mg per day of tavapadon on days 21-24 of treatment,
step 8 comprises administering to the patient a dose of a therapeutically effective amount of 5 mg per day of tavapadon,
thereby treating the Parkinson's Disease.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the method further comprises an adjustment phase following the titration phase, wherein the adjustment phase comprises:
step 9 comprising administering to the patient a dose of 10 mg per day dose of tavapadon, and
step 10 comprising administering to the patient a therapeutically effective amount of 15 mg per day dose of tavapadon;
wherein the dose of tavapadon is adjusted over the range of a therapeutically effective amount of 5, 10 or 15 mg per day of tavapadon in step 9 and step 10 based on patient tolerability.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method further comprises an adjustment phase following the titration phase, wherein the adjustment phase comprises:
step 9 comprising administering to the patient a dose of 10 mg per day dose of tavapadon, wherein a patient who is unable to increase the dose from 5 mg to 10 mg on the first day of step 9 due to tolerability issues will begin a maintenance phase at the patient's maximum tolerated dose of 5 mg per day.

### Claim 7 (depends on 5)

The method of claim 5, wherein the method further comprises a maintenance phase following the adjustment phase, wherein the maintenance phase comprises administering to the patient a therapeutically effective amount of 5, 10 or 15 mg per day dose of tavapadon, wherein the patient is administered the highest tolerated dose achieved during the adjustment phase.

### Claim 8 (depends on 7)

The method of claim 7, wherein the dose administered to the patient in the maintenance phase is a maximum tolerated dose of tavapadon.

### Claim 9 (depends on 7)

The method of claim 7, wherein tavapadon is administered to the patient in a dose of 3 or fewer oral pills.

### Claim at position 10

10-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the patient has a diagnosis of Parkinson's Disease that is consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria.

### Claim 23 (depends on 1)

The method of claim 1, wherein the patient has modified Hoehn and Yahr stage 1, 1.5, or 2.

### Claim 24 (depends on 1)

The method of claim 1, wherein the patient has modified Hoehn and Yahr stage 2, 2.5, or 3 in the “on” state and a minimum of 22 hours of “off” time on 2 consecutive days.

### Claim 25 (depends on 1)

The method of claim 1, wherein the patient has a Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score≥2 and Part III score≥10.

### Claim 26 (depends on 1)

The method of claim 1, wherein the patient is not previously treated with a medication for Parkinson's Disease.

### Claim 27 (depends on 1)

The method of claim 1, wherein the patient is previously and/or concurrently treated with a medication for Parkinson's Disease.

### Claim 28 (depends on 7)

The method of claim 7, wherein the patient is previously treated with a dopaminergic agent.

### Claim 29 (depends on 7)

The method of claim 7, wherein the patient is concurrently treated with a dopaminergic agent.

### Claim 30 (depends on 29)

The method of claim 29, wherein the dopaminergic agent is levodopa or dopamine receptor agonist.

### Claim at position 20

31-35. (canceled)

### Claim 36 (depends on 1)

The method of claim 1, wherein the method comprises administering to the patient one or more catechol-O-methyl transferase inhibitor, MAO-B inhibitor, amantadine, istradefylline, or anticholinergic drug prior to or concurrently with tavapadon.

### Claim 37

(canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the Parkinson's Disease is an early Parkinson's Disease.

### Claim 39 (depends on 7)

The method of claim 7, wherein the Parkinson's Disease is an early Parkinson's Disease.

### Claim 40 (depends on 39)

The method of claim 39, wherein the treatment results in a statistically significant and clinical meaningful improvement over placebo at Week 26 from commencement of the treatment as measured by a Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II+III Combined Score.

### Claim 41 (depends on 39)

The method of claim 39, wherein the combined score in the patient is improved by −12.1, wherein the patient is administered a therapeutically effective amount of 15 mg per day dose of tavapadon in the maintenance phase.

### Claim 42 (depends on 39)

The method of claim 39, wherein the combined score in the patient is improved by −11.5, wherein the patient is administered a therapeutically effective amount of 5 mg per day dose of tavapadon in the maintenance phase.

### Claim 43 (depends on 39)

The method of claim 39, wherein the treatment results in a statistically significant and clinical meaningful improvement over placebo at Week 26 from commencement of the treatment as measured by a Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score.

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46 (depends on 1)

The method of claim 1, wherein the Parkinson's Disease is an advanced Parkinson's Disease.

### Claim 47 (depends on 7)

The method of claim 7, wherein the Parkinson's Disease is an advanced Parkinson's Disease.

### Claim 48

(canceled)

### Claim 49 (depends on 1)

The method of claim 1, wherein the treatment results in an increased daily “on” time by about 1.1 hours without troublesome dyskinesia over placebo at Week 26 from commencement of the treatment.

### Claim 50 (depends on 1)

The method of claim 1, wherein the treatment results in a reduced daily “off” time by about 0.95 hours without troublesome dyskinesia over placebo at Week 26 from commencement of the treatment.

### Claim 51 (depends on 1)

The method of claim 1, wherein the patient exhibits improved motor control symptoms or improved motor function, as measured on the Hoehn and Yahr scale.

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

A method for treating Parkinson's Disease in a patient, wherein the method comprises:
a titration phase comprising orally administering to the patient:
0.25 mg per day dose of tavapadon for days 1-4 of the titration phase;
0.5 mg per day dose of tavapadon for days 5-8 of the titration phase;
0.75 mg per day dose of tavapadon for days 9-12 of the titration phase;
1.0 mg per day dose of tavapadon for days 13-16 of the titration phase;
1.5 mg per day dose of tavapadon for days 17-20 of the titration phase;
2.25 mg per day dose of tavapadon for days 21-24 of the titration phase;
3 mg per day dose of tavapadon for days 25-40 of the titration phase; and
a therapeutically effective amount of 5 mg per day dose of tavapadon for days 41-56 of the titration phase;
thereby treating the Parkinson's Disease.

### Claim 55

A method for treating Parkinson's Disease in a patient, wherein the method comprises:
i. a titration phase comprising orally administering to the patient:
0.25 mg per day dose of tavapadon for days 1-4 of the titration phase;
0.5 mg per day dose of tavapadon for days 5-8 of the titration phase;
0.75 mg per day dose of tavapadon for days 9-12 of the titration phase;
1.0 mg per day dose of tavapadon for days 13-16 of the titration phase;
1.5 mg per day dose of tavapadon for days 17-20 of the titration phase; 2.25 mg per day dose of tavapadon for days 21-24 of the titration phase;
3 mg per day dose of tavapadon for days 25-40 of the titration phase; and a therapeutically effective amount of 5 mg per day dose of tavapadon for days 41-56 of the titration phase;
ii. followed by an adjustment phase comprising orally administering to the patient:
a therapeutically effective amount of 10 mg per day dose of tavapadon, and
a therapeutically effective amount of 15 mg per day dose of tavapadon,
wherein the dose of tavapadon is adjusted over the range of 5, 10 or 15 mg based on patient tolerability; and
iii. followed by a maintenance phase comprising orally administering to the patient:
a therapeutically effective amount of 5, 10 or 15 mg per day dose of tavapadon;
wherein the patient is administered the highest tolerated dose achieved during the adjustment phase and the maintenance phase maintains the patient on a steady dose of tavapadon,
thereby treating the Parkinson's Disease.

### Claim 56

A method for treating Parkinson's Disease in a patient, wherein the method comprises:
i. a titration phase comprising orally administering to the patient:
0.25 mg per day dose of tavapadon for days 1-4 of the titration phase;
0.5 mg per day dose of tavapadon for days 5-8 of the titration phase;
0.75 mg per day dose of tavapadon for days 9-12 of the titration phase;
1.0 mg per day dose of tavapadon for days 13-16 of the titration phase;
1.5 mg per day dose of tavapadon for days 17-20 of the titration phase; 2.25 mg per day dose of tavapadon for days 21-24 of the titration phase;
3 mg per day dose of tavapadon for days 25-40 of the titration phase; and a therapeutically effective amount of 5 mg per day dose of tavapadon for days 41-56 of the titration phase;
ii. followed by an adjustment phase comprising orally administering to the patient: a therapeutically effective amount of 10 mg per day dose of tavapadon, and
wherein a patient who is unable to increase the dose from 5 mg to 10 mg on the first day of step 9 due to tolerability issues will begin a maintenance phase at the patient's maximum tolerated dose of 5 mg per day; and
iii. followed by a maintenance phase comprising orally administering to the patient:
a therapeutically effective amount of 5, 10 or 15 mg per day dose of tavapadon;
wherein the patient is administered the highest tolerated dose achieved during the adjustment phase and the maintenance phase maintains the patient on a steady dose of tavapadon,
thereby treating the Parkinson's Disease.

### Claim at position 42

57-72. (canceled)
